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Abstract
Aims/hypothesis We evaluated the effect of diabetic retinop-
athy on 25 year survival rate among a population-based
cohort of type 1 diabetic patients from Fyn County, Denmark.
Methods In 1973 all diabetic patients from Fyn County,
Denmark with onset before the age of 30 years as of 1 July
1973 were identified (n=727). In 1981, only 627 patients
were still alive and resident in Denmark. Of these, 573
(91%) participated in a clinical baseline examination, in
which diabetic retinopathy was graded and other markers of
diabetes measured. Mortality rate was examined in a 25 year
follow-up and related to the baseline examination.
Results Of the 573 patients examined at baseline in 1981
and 1982, 297 (51.8%) were still alive in November 2006.
Of the others, 256 (44.7%) had died, three (0.5%) had left
Denmark and 17 (3%) were of unknown status. Age- and
sex-adjusted HRs of mortality rate were 1.01 (95% CI
0.72–1.42) and 2.04 (1.43–2.91) for patients with non-
proliferative and proliferative retinopathy respectively at
baseline compared with patients with no retinopathy. After
adjusting for proteinuria, HR among patients with prolifera-
tive retinopathy lost statistical significance, but still remained
1.48 (95% CI 0.98–2.23). The 10 year survival rate of
patients who had proliferative retinopathy as well as
proteinuria at baseline was 22.2% and significantly lower
(p<0.001) than in patients with proteinuria only (70.3%),
proliferative retinopathy only (79.0%) or neither (86.6%).
Conclusions/interpretation Proliferative retinopathy and
proteinuria predict mortality rate in a population-based
cohort of type 1 diabetic patients. In combination they act
even more strongly. Non-proliferative diabetic retinopathy
did not affect survival rate.
Keywords Diabetic retinopathy . Early onset .
Microvascular complications .Mortality .
Non-proliferative retinopathy . Proliferative retinopathy .
Proteinuria . Retinopathy . Survival rate . Type 1 diabetes
Introduction
Type 1 diabetes is associated with higher all-cause mortality
rates than those seen in the general population [1–5]. This
excess mortality is mainly caused by the more frequent
development of macrovascular diseases among these
patients [2, 6–10].
The association between diabetic retinopathy and mor-
tality rate in type 1 diabetic patients has been examined in
several studies [6, 7, 10–17], but only one study was
population-based and presented long-term data [6].
In general the association between retinopathy and
mortality rate is better investigated in type 1 diabetes because
of the earlier onset and lower morbidity in this patient group
than in patients with type 2 diabetes.
The aim of the current study was to evaluate the
prognostic value of non-proliferative and proliferative
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retinopathy for survival rates in a 25 year follow-up among
a population-based cohort of type 1 diabetic patients from
Fyn County, Denmark. We also examined the role of
additional risk factors such as sex, duration of diabetes,
smoking, glycaemic control, blood pressure, BMI and
proteinuria in the above associations.
Methods
Participants All diabetic patients resident in Fyn County,
Denmark on 1 July 1973 whose onset of diabetes occurred
before the age of 30 years as of 1 July 1973 (n=727) were
previously identified on the basis of insulin prescriptions
[18, 19]. At that time, the County of Fyn had approximately
450,000 inhabitants, thus being a demographically repre-
sentative 9% sample of the Danish population [18].
In 1981 all patients still alive and resident in Denmark
(n=627, 86.2%) were invited to participate in a clinical
follow-up investigation carried out between 1 June 1981
and 1 June 1982. Of these, 577 (92.0%) participated in the
baseline examination (Fig. 1). Data for four patients were
subsequently lost, leaving baseline data available on 573
patients (321 men and 252 women). All participants gave
written informed consent.
Baseline examination The clinical baseline examination
was performed in 1981 and 1982 and included interview,
ophthalmological examination, measurement of blood
pressure, height and weight, and both blood and urine
sampling [19].
Measurement of blood pressure was performed by means
of an Erkameter sphygmomanometer (Morton Medical Ltd,
London, UK) on one arm with the patient in sitting position
after 10 min of rest. Measurements of the blood included
HbA1c, done as total HbA1 with resin 70 (Bio-Rad,
Hercules, CA, USA) at 20°C and pH 6.70. Urine protein
was considered present, if greater than or equal to 0.5 g/l
protein was found in a spot urine sample. The patients were
asked about their smoking habits. Both current and ex-
smokers were considered to be smokers for the upcoming
models.
For both eyes the best corrected visual acuity was
measured. Using tropicamide 1%, both pupils were dilated
and a slit lamp examination performed (Haag-Streit, Wedel,
Germany). Ophthalmoscopy was performed and retinopathy
was described and classified by a single trained observer. For
further analysis, the worst eye determined the patient’s level
of retinopathy, which was classified as non-proliferative or
proliferative retinopathy, if present. Non-proliferative reti-
nopathy was defined as the presence of microaneurysms,
haemorrhages, hard exudates, cotton wool spots, venous
beading or intraretinal microvascular abnormalities in the
retina. Proliferative retinopathy was defined as newly formed
vessels in addition to the above. The presence of photoco-
agulation scars as panretinal treatment was also graded as
proliferative retinopathy. Maculopathy was included in the
category of non-proliferative retinopathy. Inclusion of
patients with maculopathy in the proliferative group did not
change the results of the study (data not shown).
At baseline, 143 participants (25.0%) had no retinopathy,
291 (50.8%) had non-proliferative retinopathy and 139
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Fig. 1 Flow chart of type 1
diabetic patients from Fyn
County, Denmark
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(24.2%) had proliferative retinopathy (Table 1). On aver-
age, patients with proliferative retinopathy were older, had
a longer duration of diabetes, were more likely to be current
or former smokers, had a lower HbA1c, higher systolic and
diastolic blood pressure, and were more likely to have
proteinuria. There was no significant difference between the
groups according to sex and BMI. Mean age at baseline
examination was 38.3 years.
Follow-up In November 2006 data on mortality rates were
collected from The Danish Civil Registration System. For
those who had died, left Denmark or refused to provide
data for scientific studies, we were informed of the date of
death, emigration or refusal.
Statistical analysis Baseline characteristics are presented as
percentage or means±SD after ensuring normal distribution
of the data. Statistical significance at the 0.05 level for any
differences was tested with ANOVA for continuous
variables and Pearson’s χ2 test for categorical variables.
The follow-up duration was calculated as the time between
the baseline examination and date of death or date of loss to
follow-up. Kaplan–Meier survival curves were plotted for
all-cause mortality. Differences between curves were tested
by the log rank test.
To evaluate the effect of diabetic retinopathy on survival,
we used Cox’s proportional hazard analyses to study the
association between both non-proliferative and proliferative
retinopathy at baseline and all-cause mortality compared with
patients without retinopathy. The risks were calculated in a
basic model, adjusting for age and sex only because of the
known importance of these factors for survival rates. To
determine which associations contributed to any elevated risk,
we then made adjustments for different covariates in a one-
by-one model. In the end, all previously added factors were
included in a multivariate model in order to get an estimate of
the independent predictive power of non-proliferative and
proliferative retinopathy for all-cause mortality.
In the above model, we present our data as HRs with
95% CIs. Confidence intervals that do not include 1.0 are
regarded as statistically significant. All statistical analyses
were performed in Stata Intercooled 9.2 (StataCorp,
College Station, TX, USA).
Results
Of the 573 patients participating in the baseline examina-
tion, 297 (51.8%) were still alive 25 years later, while 256
(44.7%) had died, three (0.5%) had emigrated and data
were not available for 17 (3.0%; Fig. 1). The breakdown of
Table 1 Baseline characteristics (1981–1982) and 25 year survival rates according to level of retinopathy in type 1 diabetic patients from Fyn
County, Denmark
No retinopathy Non-proliferative retinopathy Proliferative retinopathy p value
N 143 291 139
Baseline
Age (years) 34±16 39±12 41±12 <0.0001
Sex (% male) 52 55 62 0.22
Duration diabetes (years) 20±12 22±10 27±10 <0.0001
History of smoking (%) 55 68 74 0.002
HbA1c (%) 8.73±0.67 8.66±0.81 8.29±1.15 <0.0001
SBP (mmHg) 140±24 148±22 153±26 0.0001
DBP (mmHg) 91±13 94±13 95±14 0.02
BMI (kg/m2) 22.0±2.9 22.6±2.7 22.6±2.8 0.10
Proteinuria (%) 5 8 30 <0.0001
Follow-up
Survival rate (%) 62.9 55.0 33.8 <0.0001
Data are means±SD or percentages. p values tested with ANOVA for continuous variables and Pearson’s χ2 test for categorical variables
DBP, diastolic blood pressure; SBP, systolic blood pressure
Fig. 2 All-cause mortality rate according to level of baseline
retinopathy in type 1 diabetic patients from Fyn County, Denmark.
Blue line, no retinopathy; brown line, non-proliferative retinopathy;
green line, proliferative retinopathy
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deaths was: 147 men (45.8%) and 109 women (43.3%).
There was no difference in mortality rates between the two
sexes (p=0.52).
According to level of retinopathy at baseline, 25 year
survival rate was 62.9% for patients with no retinopathy,
55.0% for patients with non-proliferative retinopathy and
33.8% for patients with proliferative retinopathy, respectively
(Fig. 2).
Age- and sex-adjusted HRs for non-proliferative retinop-
athy and proliferative retinopathy were 1.01 (95% CI 0.72–
1.42) and 2.04 (95% CI 1.43–2.91), respectively (Table 2),
compared with patients without retinopathy. HR for all-cause
mortality among patients with proliferative retinopathy was
1.49 (95% CI 0.99–2.24) when adjusted for proteinuria.
Adjusting for other covariates in a one-by-one adjustment
had only a small impact on all-cause mortality rate. In a
multivariate model, HR for proliferative retinopathy still
remained 1.48 (95% CI 0.98–2.23), although not statistically
significant. The elevated HR for all-cause mortality among
patients with proliferative retinopathy is thus explained
partly, but not entirely, by other risk factors, of which
proteinuria seems to be the most important.
In order to evaluate the combined and separate effects of
proliferative retinopathy and proteinuria on survival,
patients were divided into four groups according to the
presence and absence of proliferative retinopathy and
proteinuria at baseline (Fig. 3). The 25 year survival rate
was 66.4% for patients with neither proliferative retinopa-
thy nor proteinuria, 48.2% for patients with proliferative
retinopathy only, 33.3% for patients with proteinuria only
and 16.7% for patients who had both proliferative retinop-
athy and proteinuria at baseline (p<0.001). Mean ages at
baseline for the four groups were 36.7, 40.9, 38.6 and
41.1 years, respectively.
Interestingly, the 10 year survival rate for patients with
proliferative retinopathy and proteinuria at baseline was
22.2% versus 86.8% in the group of patients with neither
proliferative retinopathy nor proteinuria, 79.0% in those
with proliferative retinopathy only and 70.4% in the group
with proteinuria only.
Discussion
In the current 25 year follow-up study, we found a
significantly lower survival rate among type 1 diabetic patients
Fig. 3 All-cause mortality rate according to level of baseline
retinopathy and proteinuria in type 1 diabetic patients from Fyn
County, Denmark. Blue line, no proliferative retinopathy, no protein-
uria; brown line, proliferative retinopathy, no proteinuria; green line,
no proliferative retinopathy, proteinuria; orange line, proliferative
retinopathy, proteinuria
Table 2 Age- and sex-adjusted HRs for all-cause mortality according to level of retinopathy compared with patients with no retinopathy in type 1
diabetic patients from Fyn County, Denmark
All-cause mortality rate
Non-proliferative retinopathy Proliferative retinopathy
HR (95% CI) p value HR (95% CI) p value
Model 1: age, sex 1.01 (0.72–1.42) 0.97 2.04 (1.43–2.91) <0.001
One-by-one adjustment
Model 1 and diabetes duration 1.01 (0.72–1.42) 0.97 1.96 (1.36–2.80) 0.001
Model 1 and smoking 1.01 (0.73–1.43) 0.92 2.01 (1.41–2.87) <0.001
Model 1 and HbA1c 1.07 (0.76–1.51) 0.71 2.16 (1.51–3.09) <0.001
Model 1 and SBP 1.00 (0.71–1.41) 0.99 2.02 (1.42–2.89) <0.001
Model 1 and DBP 1.01 (0.71–1.41) 0.98 2.03 (1.42–2.90) <0.001
Model 1 and BMI 1.04 (0.73–1.47) 0.85 2.06 (1.42–2.97) <0.001
Model 1 and proteinuria 0.98 (0.68–1.41) 0.90 1.49 (0.99–2.24) 0.054
Multivariate model
Model 1 plus a 0.98 (0.68–1.42) 0.91 1.48 (0.98–2.23) 0.060
HR (95% CI) for all-cause mortality rate analysed by Cox’s proportional hazards analyses
DBP, diastolic blood pressure; SBP, systolic blood pressure
aModel 1 plus diabetes duration, smoking, HbA1c, SBP, DBP, BMI and proteinuria
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who had proliferative retinopathy compared with patients
who had no retinopathy or non-proliferative retinopathy,
respectively. Adjusted for age and sex, the HR for all-cause
mortality was 2.04 (95% CI 1.43–2.91) for proliferative
retinopathy and 1.01 (95% CI 0.72–1.42) for non-prolifer-
ative retinopathy, respectively. After adjusting for other risk
factors, the HR for proliferative retinopathy was no longer
statistically significantly increased, but remained at 1.48
(95% CI 0.98–2.23). We found that proliferative retinop-
athy and proteinuria were the only important markers of
mortality rate. The 10 year survival rate was only 22.2% for
patients who had both proliferative retinopathy and pro-
teinuria at baseline. This was significantly lower than for
patients who had only proliferative retinopathy, only
proteinuria or neither.
Our study has several limitations. Baseline data were
collected in 1981 and 1982. The methods available then
would not live up to the standards of today. Ophthalmos-
copy was used to grade retinopathy, as fundus photography
was not available. Retinopathy was found in 75.0% (430 of
573) patients after a mean duration of 23 years. Other
studies have shown the prevalence of retinopathy after
20 years to be more than 80% [20–22]. The explanation of
this could be that retinopathy was misclassified in some of
our patients due to the lower sensitivity of ophthalmoscopy
compared with fundus photography [23]. Moreover, differ-
entiation between different degrees of non-proliferative
retinopathy was not performed. Subclassification of non-
proliferative retinopathy might have given valuable addi-
tional information. We used a single spot of urine to
evaluate whether proteinuria was present. The standard
today is to use multiple collections due to the substantial
intra-individual variability in urinary albumin excretion rate
[24]. Furthermore, in our study, analysis for microalbumi-
nuria was not available at the time of the baseline
examination.
Population-based long-term data on survival rates among
type 1 diabetic patients according to level of retinopathy at
baseline has only been presented in two earlier studies. In a
16 year follow-up of the Wisconsin Epidemiologic Study of
Diabetic Retinopathy, Klein et al. found severity of
retinopathy at baseline to be associated with all-cause and
ischaemic heart disease mortality rates among 996 younger
onset patients [6]. Adjusted for age and sex, all-cause HR in
that study was 5.53 (95% CI 3.06–9.99) for patients with
proliferative retinopathy at baseline. After adjusting for
other risk factors this association lost significance (HR
1.28, 95% CI 0.62–2.62). It was stated that the greatest
impact on reducing the HRs came when blood pressure or
gross proteinuria was added as adjusting risk factor to the
model. In an 8 year follow-up in the EURODIAB
Prospective Complications Study, van Hecke et al. [11]
examined mortality according to level of retinopathy at
baseline among 2,237 European type 1 diabetic patients.
The age- and sex-adjusted HR of all-cause mortality was
4.16 (95% CI 1.96–8.84) in patients with proliferative
retinopathy. In a multivariate model this was no longer
statistically significant, albeit still increased (HR 2.06, 95%
CI 0.63–6.73). Although many patients were included, the
study was biased in that it was not population-based. To our
knowledge, the combined effect of retinopathy and renal
dysfunction on mortality rate has only been established in
type 2 diabetes [25, 26].
In conclusion, we found both proliferative retinopathy
and proteinuria to be independent markers of mortality rates
among type 1 diabetic patients. In combination they
strongly predicted mortality rate. For patients with both
complications, the 10 year survival rate was only 22.2%.
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